Agribusiness Sector Heats Up: BASF, MustGrow Biologics, and Corteva—Where Growth Is Scaling and What Analysts Recommend

BASF: In-House Development and Fermentation in Focus

The German chemical company BASF is strictly aligning its agricultural division with the 2030 sustainability goals and aims to expand its market share for environmentally friendly products in a targeted manner. Rather than relying primarily on acquiring plant-based solutions, as other industry giants do, BASF focuses on discovering biological microbial strains and relies on its own fermentation facilities for industrial production. Furthermore, the company is actively forming alliances in the hardware sector. Together with its partner AMVAC, BASF is integrating the Rhizo-Flo granule into the SIMPAS precision application system. BASF is focusing on specific areas within the biologics sector but aims to grow even further in this promising niche.

Corteva: Course Set After Active Ingredient Phase-Out

Following its regulatory-mandated phase-out of the insecticide chlorpyrifos, the US-based company Corteva is aiming for a leading role in the market for sustainable agricultural solutions. To this end, management established a dedicated division and strengthened it through the acquisition of specialists such as Symborg. Through this acquisition, Corteva secured global rights to the microorganism Methylobacterium symbioticum, which colonizes leaves and fixes nitrogen directly from the air, thereby reducing the need for fertilizer. In addition, Corteva is expanding its portfolio through collaborations and licensing agreements with competitors. Corteva's focus is thus primarily on microbiomes and acquisitions.

MustGrow Biologics: Revolutionizing Organic Crop Protection Thanks to Mustard Seeds

The Canadian agtech company MustGrow Biologics relies on the extraction of natural active ingredients from mustard seeds, and its products deliver remarkable results. Using enzymatic processes, MustGrow extracts biologically active compound from mustard that form in situ allyl isothiocyanate, which is the spice we taste when we eat mustard products. With its proprietary liquid formulation TerraMG™, MustGrow Biologics has succeeded in keeping the volatile active ingredient stable until application, after which the product rapidly degrades in the soil within 48-72 hours. Numerous field trials demonstrate that the biopesticide significantly reduces infestation in most cases and is highly efficacious compared to synthetic agents such as chloropicrin. Applications of TerraMG™ range from soil treatment against fungi such as Fusarium or Verticillium to post-harvest treatment of potatoes. In addition, the company markets TerraSante™, a biological soil fertility product designed to enhance soil microbiome activity.

Global Licenses and Targeted Collaborations for Greater Scale

To unlock the technology's full potential, MustGrow Biologics is focusing on global licensing and collaboration with partners. A key foundation is an exclusive commercialization and licensing agreement with Bayer, which has been in place since 2023 for the regions of Europe, the Middle East, and Africa. Bayer is covering all costs for regulatory submissions, field development, and trials. MustGrow Biologics' management estimates the total value of upfront and milestone payments, as well as market-related development contributions from Bayer, at USD 35 million to USD 40 million over a period of 5 to 7 years, excluding future revenue shares. Demand for MustGrow's solutions appears to be high. The company closed its distribution subsidiary in April 2026 and announced that it would focus on increasing production of TerraSante™ through external partnerships.

Conclusion: MustGrow Biologics Earns Analysts' Confidence

MustGrow Biologics may be an attractive opportunity based on its current fundamentals. In a commissioned study, analysts at GBC AG forecast a sharp increase in revenue from CAD 4.5 million in 2026 to more than CAD 31.5 million by 2028. The analysts have assigned a price target of CAD 2.70 and maintain a "Buy" recommendation. Key catalysts for future growth include the continued expansion of the company's North American commercial operations and upcoming milestones in its licensing partnership with Bayer. Key risks include potential commercialization delays and fluctuations in the prices of raw materials, such as mustard seed. After a significant share price decline in recent months, MustGrow's market capitalization has fallen to approximately CAD 22 million. For investors with a higher risk tolerance, the stock could represent an opportunity to gain exposure to the growing market for innovative agricultural solutions.